	Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery. Eur Urol Open Sci Tazawa S, Shinohara M, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Narita T, Fujita N, Mikami J, Okamoto T, Yamamoto H, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S. PMID: 42164551 [PubMed]
	The role of CD36 in renal and bladder cancer. Discoveries (Craiova) Pavalean MI, Madan VL, Pavalean MC, Ceafalan LC, Hinescu ME. PMID: 42164471 [PubMed]
	Meta-analysis of efficacy comparisons between standard- and low-dose Bacillus Calmette-Guerin vaccines in managing non-muscular invasive bladder cancer. Oncol Lett Liu X, Bao Y. PMID: 42164465 [PubMed]
	Bioinformatics analysis and experimental approach identify BRD-family gene DSP as a diagnostic and prognostic indicator in bladder cancer. Transl Androl Urol Liu Z, Tan T, Li S, Wang Y. PMID: 42164400 [PubMed]
	Advancing bladder cancer detection: commentary on a urinary DNA methylation diagnostic assay. Transl Androl Urol Duquesne I, Chakra MA, Myers AA, Boormans JL, Hayne D, Brown JA, O'Donnell MA. PMID: 42164398 [PubMed]
	Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study. Transl Androl Urol Xia Y, Ma B, Huang T, Liu X. PMID: 42164394 [PubMed]
	Single-port robotic surgery for kidney and upper tract cancer: a narrative review. Transl Androl Urol Daher K, Soputro NA, Younis SK, Al-Bayati A, Bernardino R, Watfa M, Rai S, Wang L, Ghandour R, Kaouk J, Autorino R. PMID: 42164392 [PubMed]
	Machine learning-based integration identifies lactylation biomarkers for prognosis prediction and tumor microenvironment modulation in bladder cancer. Transl Androl Urol Zhou X, Weng L, Sun T, Jiang Q, Zeng F, Xu C, Chang C, Wang Y, Zhou J. PMID: 42164391 [PubMed]
	Association between systemic inflammatory response index and the prognosis of patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis. Transl Androl Urol Dai Q, Tan X, Huang P, Zhang J, Zhu H. PMID: 42164378 [PubMed]
	Prostate imaging reporting and data system version 2.1 as a predictor of clinically significant and aggressive prostate cancer: a radical prostatectomy-validated study. Transl Androl Urol Pisuchpen N, Eurboonyanun K, O'Shea A, Lahoud RM, Atre ID, Harisinghani M. PMID: 42164375 [PubMed]
	Distant metastasis prediction in renal carcinoma: a retrospective cohort study using interpretable machine learning. Transl Androl Urol Wang Y, Chen Y, Zhou Z, Ding Y, Yuan J. PMID: 42164374 [PubMed]
	Identification and diagnostic model construction of cuproptosis-related biomarkers in bone metastatic prostate cancer. Transl Androl Urol Li J, Yao S, Luo J, Li T, Zhang J. PMID: 42164373 [PubMed]
	Bibliometric study on hotspots and trends of immunotherapy for kidney cancer from 2014 to 2024. Transl Androl Urol Guo Q, Nie Z. PMID: 42164368 [PubMed]
	Prostate cancer screening and evidence: the role of overall survival. Transl Androl Urol Takahashi T. PMID: 42164360 [PubMed]
	Urinary PENK DNA methylation for bladder cancer diagnosis: methodological rigor, interpretive boundaries, and the evidence required for clinical translation. Transl Androl Urol Delrue C, Oyaert M, Speeckaert MM. PMID: 42164358 [PubMed]
	Insurance Network Status and 1-Year Health Care Utilization and Outpatient Costs Among Commercially Insured Patients With Newly Diagnosed and Non-Definitively Treated Prostate Cancer, 2010-2021. Cancer Med Grutman AJ, Alshak MN, Higgins MI, Pavlovich CP, Ng DK. PMID: 42163058 [PubMed - indexed for MEDLINE]
	Performance of a self-attention-based model in the task of differentiating clear cell renal cell carcinoma from other renal tumors: variable Vision Transformer (vViT). Br J Radiol Usuzaki T, Takahashi K, Takagi H, Ishikuro M, Obara T, Inamori R, Kamada H, Sato T, Oguro S, Takase K. PMID: 42162958 [PubMed - as supplied by publisher]
	Correction: Multiclass Classification of Renal Tumor Subtypes: Addressing Diagnostic Challenges Using a Texture-Informed Deep Hybrid CNN-Transformer. J Imaging Inform Med Azam MT, Balaha HM, Aboudessouki A, Ali KM, Ali A, El-Melegy MT, Idrees MT, Ghazal M, Khalil A, Gondim DD, El-Baz A. PMID: 42162525 [PubMed - as supplied by publisher]
	CCDC78 is required for prostate cancer cell growth and serves as a prognostic biomarker for high-risk disease. Discov Oncol Zhu L, Liang W. PMID: 42162449 [PubMed - as supplied by publisher]
	Predictive risk model for bone metastasis in intermediate-risk prostate cancer: a single-center retrospective analysis. Sci Rep Zhu J, Shen C, Wang Z, Chen F, Wang T. PMID: 42162156 [PubMed - as supplied by publisher]

Articles 1 - 20 / 178395

Page 1 of 8920



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy